Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus

NCT ID: NCT06498284

Last Updated: 2025-04-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-25
• Study Completion Date: 2024-09-06

Brief Summary

The purposes of this study are to:

• Evaluate the safety and tolerability of the study drug.
• Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get rid of them.
• Measure the amount of glucose (blood sugar) and a substance called C-peptide in the bloodstream after receiving the study drug.

Researchers will compare the study drug to a placebo (a look-alike substance that contains no drug).

Participants will:

• Stay 5 days and 4 nights or 6 days and 5 nights at the research site, and have a follow-up phone call 7 days after leaving the research site.
• Take one (1) dose of the study drug or placebo
• Have blood taken to measure the amount of study drug and its breakdown product and the levels of glucose and C-peptide
• Have safety tests such as vital sign, ECGs, and glucose measurements

Conditions

Diabetes Mellitus, Type II

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

HM-002-1005 61.5 mg or matching placebo

Single dose of 61.5 mg HM-002-1005 or matching placebo

Group Type: EXPERIMENTAL

HM-002-1005

Intervention Type: DRUG

HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

HM-002-1005 123 mg or matching placebo

Single dose of 123 mg HM-002-1005 or matching placebo

Group Type: EXPERIMENTAL

HM-002-1005

Intervention Type: DRUG

HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

HM-002-1005 184.5 or 246 mg, or matching placebo

Single dose of 184.5 or 246 mg HM-002-1005 or matching placebo

Group Type: EXPERIMENTAL

HM-002-1005

Intervention Type: DRUG

HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

HM-002-1005 369 mg or matching placebo

Single dose of 369 mg HM-002-1005 or matching placebo

Group Type: EXPERIMENTAL

HM-002-1005

Intervention Type: DRUG

HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

Interventions

HM-002-1005

HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

Intervention Type: DRUG

Other Intervention Names

1005

Eligibility Criteria

Inclusion Criteria

1. Males or females, of any race, between 18 and 65 years of age, inclusive.

2. Body mass index between 18.5 and 38.0 kg/m2, inclusive.

3. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.

4. Type 2 diabetes mellitus, as determined by the American Diabetes Association (ADA) Standard Care Diagnostic Criteria 2023, and

1. are drug naïve, treated with diet and exercise, or

2. have been on a stable dose of ≤2000 mg metformin for ≥1 month, or

3. have been on a stable dose of antidiabetic medications (other than metformin) for ≥90 days.

5. Except for findings consistent with T2DM, in good health, determined from medical history, 12 lead electrocardiogram (ECG), vital signs measurements, clinical laboratory evaluations, and physical examinations at screening and/or check in, as assessed by the investigator (or designee).

6. Glycated hemoglobin between 6.5% and 9.5%, inclusive.

7. Fasting plasma glucose between 126 and 196 mg/dL (7 and 11 mmol/L, respectively), inclusive. Testing may be repeated once, at the discretion of the investigator (or designee).

Other Inclusions

8. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion Criteria

1. Type 1 diabetes mellitus, maturity onset diabetes of the young, or diabetes mellitus caused by damage to the pancreas or any other condition (eg, acromegaly or Cushing's syndrome).

2. Diabetic neuropathy, retinopathy, or nephropathy.

3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis.

4. History of severe hypoglycemia, defined as severe cognitive impairment requiring external assistance for recovery within 3 months prior to dosing; or recurrent hypoglycemia (Level 2), defined as ≥2 episodes within 3 months prior to dosing; or ADA Level 3 hypoglycemia within 6 months prior to dosing.

5. Hypoglycemia unawareness or asymptomatic hypoglycemia.

6. Clinically significant history of liver disease (eg, hepatitis and cirrhosis) within 1 year prior to screening.

7. Clinically significant history of renal disease. Mild to moderate chronic kidney disease is permitted.

8. Clinically significant history of cardiovascular disease, particularly coronary artery disease, arrhythmias, atrial tachycardia, or congestive heart disease within 1 year prior to screening. Managed hypertension is permitted.

9. Clinically significant history of any central nervous system disease, including transient ischemic attack, stroke, seizure disorder, depression, or behavioral disturbances within 1 year prior to screening.

10. Clinically significant gastric emptying abnormality (eg, severe diabetic gastroparesis or gastric outlet obstruction) or have had gastric bypass surgery.

11. Clinically significant or unstable history of any hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator (or designee).

12. Known or active malignancy, except basal cell carcinoma and cutaneous squamous cell carcinoma.

13. Any hospital admission or major surgery within 90 days prior to screening.

14. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).

15. Fasting C peptide <0.81 ng/mL.

16. Alanine aminotransferase, aspartate aminotransferase, or gamma glutamyl transferase >2 × the upper limit of normal (ULN); or total bilirubin >1.5× ULN.

17. Uncontrolled hypertriglyceridemia >500 mg/dL.

18. Estimated glomerular filtration rate ≤45 mL/min/1.73 m2, as calculated using the 2021 Chronic Kidney Disease Epidemiology equation.

19. QT interval corrected for heart rate using Fridericia's method >450 msec.

20. Positive hepatitis panel and/or positive human immunodeficiency virus test .

21. Positive pregnancy test.

22. Use of insulin, sulfonylureas, and glinides (eg, repaglinide and nateglinide).

23. Use of any strong or moderate cytochrome P450 (CYP) 3A4 inducers within 28 days prior to dosing or any strong or moderate CYP3A4 inhibitors within 7 days or 5 half lives, whichever is longer, prior to dosing.

24. Use of any P glycoprotein inducers within 14 days prior to dosing or any P glycoprotein inhibitors within 5 days or 5 half lives, whichever is longer, prior to dosing

26. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days.

27. Positive alcohol test result, or positive urine drug screen (confirmed by repeat), or positive cotinine test at screening or check in.

28. Current drug abuse, defined as the use of any illegal substance or misuse or excessive used of over the counter or prescription drugs; or current alcohol abuse, defined as the inability to stop or control alcohol use, despite adverse social or health consequences.

29. Consumption of alcohol, or caffeine containing foods or beverages within 48 hours, or foods and beverages containing grapefruit or Seville oranges within 7 days prior to check in.

30. Use of tobacco or nicotine containing products within 6 months prior to check in.

31. Receipt or donation of >1 unit (approximately 450 mL) of blood products within 3 months prior to screening.

32. Poor peripheral venous access.

33. Subjects who, in the opinion of the investigator (or designee), should not participate in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hua Medicine Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexander N Prezioso, MD

Role: PRINCIPAL_INVESTIGATOR

Clinical Pharmacology of Miami

Locations

Clinical Pharmacology of Miami

Hialeah, Florida, United States

Countries

United States

Other Identifiers

HMM0125

Identifier Type: -

Identifier Source: org_study_id